Drais Pharmaceuticals, Inc. is a privately held drug development company based in Bridgewater, New Jersey. We are focused on early and mid-stage clinical development, through proof of concept, with a current pipeline of three compounds (see Pipeline). The management team consists of highly experienced, seasoned individuals with outstanding track records in the pharmaceutical industry. Prior to forming Drais, the management team founded AkaRx, Inc., successfully guiding their lead compound into Phase 2 proof of concept and negotiating the sale of the company to Eisai, Inc. in 2010.
Drais acquires or in-licenses its compounds from large Pharma. Our business model is to set up a virtual company to house each compound in our pipeline. We acquire compounds from innovators who retain some interest in the project, but rely upon Drais to rapidly advance the compound through key development milestones in a capital and resource efficient manner. This model allows for flexible financing as well as flexible exit strategies for each pipeline compound. Our small internal team provides development services to each virtual company using an extensive network of vendors. Our internal experts are able to move compounds rapidly through key development milestones and decision points, thus de-risking programs early in development, and offering them back to the originator or other partner for later stage development and commercialization.
Drais has strong ties throughout academia and the international pharmaceutical community and has a uniquely close relationship with Astellas Pharma, Inc. of Tokyo, Japan.
For more information, see Partnerships.